Bruce Neal's Publications

About Bruce Neal's Publications

Executive Director, The George Institute for Global Health, Australia

  • 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

    Diabetes Date published:

  • Deconstructing the Supermarket: Systematic Ingredient Disaggregation and the Association between Ingredient Usage and Product Health Indicators for 24,229 Australian Foods and Beverages

    Nutrients Date published:

  • Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial

    American Journal of Kidney Diseases Date published:

  • Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

    Stroke Date published:

  • Budget impact and cost-effectiveness analyses of the COBRA-BPS multicomponent hypertension management programme in rural communities in Bangladesh, Pakistan, and Sri Lanka

    The Lancet Global Health Date published:

  • Healthy Food Prescription Programs and their Impact on Dietary Behavior and Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis

    Advances in Nutrition Date published:

  • Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease

    Circulation Date published:

  • Corrigendum

    ESC Heart Failure Date published:

  • Pseudofolliculitis Barbae in the Military and the Need for Social Awareness

    Military Medicine Date published:

  • Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

    The Lancet Date published:

  • Sodium, Blood Pressure, and the Likely Massive Avoidable Burden of Cardiovascular Disease

    Circulation Date published:

  • The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

    Kidney International Date published:

  • Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial

    Cardiovascular Research Date published:

  • POS-223 Clinical Utility of KidneyIntelX in Patients with Early Stages of Diabetic Kidney Disease in CANVAS Participants

    Kidney International Reports Date published:

  • Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

    The Lancet Oncology Date published: